Regulus Therapeutics (RGLS)
(Delayed Data from NSDQ)
$1.51 USD
+0.02 (1.34%)
Updated Nov 6, 2024 03:59 PM ET
After-Market: $1.51 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth B Momentum D VGM
Regulus (RGLS) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$10.80 | $28.00 | $3.00 | 624.83% |
Price Target
Based on short-term price targets offered by five analysts, the average price target for Regulus comes to $10.80. The forecasts range from a low of $3.00 to a high of $28.00. The average price target represents an increase of 624.83% from the last closing price of $1.49.
Analyst Price Targets (5 )
Broker Rating
Regulus currently has an average brokerage recommendation (ABR) of 1.40 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by five brokerage firms. The current ABR compares to an ABR of 1.40 a month ago based on five recommendations.
Of the five recommendations deriving the current ABR, four are Strong Buy, representing 80% of all recommendations. A month ago, Strong Buy represented 80%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 4 | 4 | 4 | 4 | 4 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.40 | 1.40 | 1.40 | 1.40 | 1.40 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
10/8/2024 | H.C. Wainwright & Co. | Raghuram Selvaraju | Strong Buy | Strong Buy |
8/9/2024 | Wells Fargo Securities | Yanan Zhu | Hold | Hold |
8/8/2024 | SVB Securities | Joseph P Schwartz | Strong Buy | Strong Buy |
8/2/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
6/25/2024 | Canaccord Genuity | Whitney Ijem | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.40 |
ABR (Last week) | 1.40 |
# of Recs in ABR | 5 |
Average Target Price | $10.80 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 92 of 252 |
Current Quarter EPS Est: | -0.18 |
RGLS FAQs
Regulus Therapeutics Inc. (RGLS) currently has an average brokerage recommendation (ABR) of 1.40 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 5 brokerage firms.
The average price target for Regulus Therapeutics Inc. (RGLS) is $10.80. The current on short-term price targets is based on 3 reports.
The forecasts for Regulus Therapeutics Inc. (RGLS) range from a low of $3 to a high of $28. The average price target represents a increase of $615.23 from the last closing price of $1.51.
The current UPSIDE for Regulus Therapeutics Inc. (RGLS) is 615.23%
Based on short-term price targets offered by five analysts, the average price target for Regulus comes to $10.80. The forecasts range from a low of $3.00 to a high of $28.00. The average price target represents an increase of 624.83% from the last closing price of $1.49.